High-dose melphalan (HDM) with peripheral blood stem cell transplant (PBSCT) is a common treatment for patients with multiple myeloma (MM) and more recently also with AL amyloidosis (ALA). We report two female patients with severe renal failure who underwent treatment with HDM for MM (patient 1) and ALA (patient 2). Both patients developed severe encephalopathy with generalised tonic-clonic seizures and a Glasgow Coma Scale (GCS) of 3/15. Causes for coma such as infections, metabolic disturbances, cerebral ischaemia or haemorrhage were excluded. Patient 1 died on day 25 post transplant while comatose. Patient 2 recovered from her comatose state 18 days after transplantation. To our knowledge this is the first report on a possible role of high-dose melphalan in the development of encephalopathy. Keywords: myeloma; high-dose melphalan; renal failure; peripheral blood stem cell transplant; encephalopathy High-dose melphalan (HDM) (140-200 mg/m 2 ) with PBSCT is a commonly used treatment for younger patients with multiple myeloma (MM). In one randomised study it was shown to improve response rate, event-free survival and overall survival when compared to conventional-dose chemotherapy.
) with PBSCT is a commonly used treatment for younger patients with multiple myeloma (MM). In one randomised study it was shown to improve response rate, event-free survival and overall survival when compared to conventional-dose chemotherapy. 1 More recently is has also been used for ALA. 2 There is no consensus about the necessity of melphalan dose reduction in patients with impaired renal function and there is only a little information about the toxicity profile of melphalan when used in high doses in patients with renal impairment.
We report two female patients who underwent treatment with HDM for MM (patient 1) and ALA (patient 2).
Case reports

Patient 1
Patient 1 was a 54-year-old woman from Pakistan who first presented with myeloma (Salmon-Durie stage 3) and renal failure due to Bence-Jones proteinuria in October 1996. She obtained a complete remission after six cycles of treatment with infused vincristine and adriamycin and oral dexamethasone (VAD). She was scheduled for HDM with PBSCT 1 year after diagnosis. The conditioning treatment consisted of cyclophosphamide 300 mg/m 2 i.v. on day Ϫ7, melphalan 140 mg/m 2 i.v. on day 0 and methylprednisolone 1.5 g i.v. from days 0 to ϩ4. The melphalan dose was reduced from the planned dose of 200 mg/m 2 because the creatinine clearance was only 18 ml/min. On day 6 post PBSCT she developed blood stained diarrhoea and WHO grade 4 oral mucositis. Escherichia coli sepsis occurred on day ϩ7 which was treated with tazocin and netilmicin. Doses of netilmicin were adjusted according to plasma levels. Tazocin was given at the dose recommended for severe renal impairment. On day 18, while still having profuse diarrhoea, she became increasingly drowsy. She was apyrexial with an oxygen saturation of 96% on air. There were no focal neurological signs. Her pupils were equal with a sluggish reaction to light, the vestibular ocular reflex was attenuated and the muscle tone was flaccid. Over the next 24 h her Glasgow Coma Scale (GCS) fell to 3/15. She developed facial grimacing and tonic-clonic seizures. Her peripheral blood film showed evidence of bone marrow recovery, blood cultures were negative, there was no electrolyte imbalance and the plasma ammonia level was normal. A CT of the brain was normal; although the maxillary sinuses were filled with fluid no organisms were cultured. The CSF was normal.
She died 23 days after PBSCT from respiratory arrest. For religious reasons, a post mortem was denied by the patient's family.
Patient 2
Patient 2 was a 52-year-old Caucasian woman who presented in July 1997 with proteinuria of 2.4 g/day. Over the following 2 months her condition rapidly progressed to dialysis-dependent renal failure. A renal biopsy revealed AL amyloid. EA bone marrow aspirate showed 20% plasma cells. No paraprotein was found and a skeletal survey was normal. SAP scintigraphy confirmed a large total body amyloid load with abnormal uptake in liver, spleen and kidneys, but no advanced cardiac amyloid.
The patient was treated with pulsed dexamethasone (40 mg/day every 3 weeks) without disease response and was admitted for HDM with PBSCT 6 months after diagnosis. The conditioning treatment consisted of cyclophos-phamide 300 mg/m 2 i.v. on day Ϫ7, melphalan 200 mg/m 2 on day Ϫ1 and methylprednisolone 1.5 g i.v. on days 0 to ϩ4. Haemodialysis was performed on alternate days including 24 h before and after HDM and 48 h after PBSCT. On day ϩ3 she complained of dysphagia, retrosternal chest pain and bloody diarrhoea. The platelet count was kept Ͼ30 ϫ 10 9 /l by platelet transfusions. An enterococcus and staphylococcus septicaemia developed which resolved with intra-venous tazocin, netilmicin and vancomycin. Dose adjustments were made after measuring plasma levels for netilmicin and vancomycin. No levels were taken for tazocin, but the patient received 4.5 g of tazocin at 12 h intervals according to guidelines for severe renal impairment mentioned in the data sheet. On day ϩ8 she became increasingly drowsy and her GCS deteriorated gradually to 3/15. She developed facial grimacing and tonic seizures. There were no focal neurological abnormalities and the vestibular-ocular reflex was attenuated indicating profound coma. No organisms were obtained from blood culture and no metabolic abnormality was found. The plasma ammonia level was normal. CT of the brain and MRI of the brain stem were normal. PCR of the CSF was negative for CMV, HSV, EBV and VZV, and culture did not reveal any organisms. On day 10 antibiotic treatment was stopped in order to exclude a drug side-effect. On day 12 her absolute neutrophil count was Ͼ1 ϫ 10 9 /l but she continued to have melaena and there was no improvement in her consciousness level. She was given supportive treatment and on day 18 regained consciousness. Since then she has made a steady recovery. One year later she is well and has had a significant reduction in her amyloid load. She remains, however, dialysis-dependent.
Discussion
HDM (200 mg/m
2 ) with PBSCT has become a standard treatment for younger patients with MM. One randomised prospective study of HDM with PBSCT showed improvement in response rate, event-free survival and overall survival in comparison to conventional chemotherapy. 1 In that study a dosage of 140 mg/m 2 was used in conjunction with total body irradiation and patients with a serum creatinine of Ͼ150 mol/l were not randomised to receive highdose treatment.
Our two patients had severe renal impairment. Patient 1 had a creatinine clearance of 18 ml/min and received 140 mg/m 2 of melphalan; patient 2 was on haemodialysis and received 200 mg/m 2 . Both patients developed severe haemorrhagic mucositis and progressive encephalopathy. No infective, metabolic or haemorrhagic cause for the coma was found. Seizures are well described as a side-effect of high doses of benzylpenicillin. Neurological side-effects are less common after treatment with penicillin derivatives. Since piperacillin was launched there has been only one report of drug-induced encephalopathy and two reports of grand mal seizures to the Medical Control Agency and there is one case report of encephalopathy in a patient on piperacillin. 3 In a large review of 20 major trials assessing the use of tazocin in a total of 2970 patients neurological side-effects were not described. 4 Dose adjustment for renal failure was performed according to the published literature. 5 After exclusion of other causes for progressive encephalopathy toxicity from the conditioning treatment remains a possible explanation.
Other groups have suggested that patients with renal impairment and myeloma can be safely treated with highdose melphalan. Supporting the possibility that melphalan may have contributed to the neurological disturbance in these two patients there are two reports of accidental overdose with melphalan associated with decreased level of consciousness, seizures and muscular paralysis. 6, 7 Pharmacokinetic parameters of melphalan such as total body clearance, elimination half-life, steady-state volume of distribution, mean residence time and area under the plasma concentration time curve significantly correlate with creatinine clearance. 8 On the other hand, melphalan clearance shows large inter-individual variation and some patients with normal renal function eliminate the drug less effectively than do other patients with severe renal impairment. 8 Intermediate-dose melphalan (60 mg/m 2 ) has been used in oliguric renal failure without any major sideeffects 9 and apart from our case there is one further published report on a successful autologous PBSCT using melphalan 140 mg/m 2 in a 49-year-old patient with MM on haemodialysis. 10 He received 140 mg/m 2 melphalan with total body irradiation and dialysis was performed every other day. This patient developed severe mucositis as the only adverse event and remained dialysis-dependent.
Other groups have suggested that patients with renal impairment and myeloma can be treated safely with highdose treatment. Ballester et al 11 published a series of six patients with MM and chronic renal failure. Three of them were dialysis-dependent at the time of transplant and the median pre-transplant serum creatinine was 5.6 mg/dl. The conditioning treatment, however, consisted of busulphan 1 mg/kg every 6 h for 16 doses and cyclophosphamide at 60 mg/kg/day for 2 days. There was one toxicity-related death due to a large subdural haematoma.
The Little Rock investigators assessed melphalan pharmacokinetics and toxicity in six patients with a creatinine clearance of Ͻ40 ml/min. 12 Five of them were dialysisdependent. 100 mg/m 2 of melphalan were given on 2 consecutive days. Renal failure was associated with longer duration of fever and hospitalisation. There were no transplantrelated deaths. A marked inter-individual variation in melphalan elimination was observed and pharmacokinetically guided dosing suggested.
Although it cannot be proven definitely that melphalan was the agent responsible for the development of progressive encephalopathy in our patients it is at least a possibility. The benefits of HDM in patients with plasma cell dyscrasia and renal failure remains uncertain.
